¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Chronic leukaemia of unspecified cell type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
¿µ¹® reserve cell ÇÑ±Û ¿¹ºñ¼¼Æ÷
¼³¸í   
  ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼­ À̹̠ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇϸ頸ŲãÁö´Â ±× ¹Ø¿¡ Àִ ¹ÌºÐÈ­¼¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ Àִ ÀÛÀº ¹ÌºÐÈ­ »óÇÇ ¼¼Æ÷.
¿µ¹® stem cell ÇÑ±Û Áٱ⼼Æ÷, °£¼¼Æ÷
¼³¸í   
  Àڱ⠺¹Á¦¸¦ ÇÏ¿© ÀÚ½ÅÀ» Á¸¼Ó½ÃŰ¸é¼­ ÇÑÆíÀ¸·Î´Â Áõ½Ä°ú ºÐÈ­¸¦ ÇÏ¿© »õ·Î¿î ¼¼Æ÷¸¦ Çü¼ºÇϴ ¼¼Æ÷·Î¼­ Á¶Ç÷Áٱ⼼Æ÷°¡ ´ëÇ¥ÀûÀÌ´Ù. Á¶Ç÷Áٱ⼼Æ÷´Â °ñ¼ö¿¡ Àִ ¼¼Æ÷·Î¼­ ¸ðµç Ç÷±¸¼¼Æ÷°¡ ¿©±â¿¡¼­ ºÐÈ­µÇ¾î ¹ß»ýÇÑ´Ù.
¿µ¹® renal cell carcinoma ÇÑ±Û ÄáÆÏ¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÄáÆÏ¿¡ »ý±ä ¿ø½ÃÄáÆÏÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ ¾Ï. ÁַΠ¿ø½Ã¼¼´¢°üÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ´Ù. ´ëÇ¥ÀûÀΠ¼¼Æ÷Á¶Á÷ÇüÀº ¿°»ö½Ã ¼¼Æ÷ÁúÀÌ ¸¼°Ô ºñ¾îº¸À̴ ¸¼Àº¼¼Æ÷¾ÏÁ¾ÀÌ´Ù. Ä¡·á´Â ¼ö¼ú°ú Ç×¾ÏÈ­Çпä¹ýÀ̸砾ÆÁÖ µå¹°Áö¸¸ ÀúÀý·Î ³´´Â °æ¿ìµµ Àִ °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù.
¿µ¹® squamous cell carcinoma ÇÑ±Û ÆíÆò¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÆíÆò¼¼Æ÷ ±â¿øÀÇ ¾ÏÀ¸·Î¼­, ÆíÆò¼¼Æ÷°¡ Àִ ¾î¶² °÷¿¡¼­µç ¹ß»ý°¡´ÉÇÔ. µû¶ó¼­ ½Äµµ¾Ï, ÇǺξÏ, Æó¾Ï, ÀڱþϠµîÀÌ ¿©±â¿¡ ÇØ´çµÈ´Ù. Æ¯È÷ ÇǺξÏÀº ¸¹Àº Àڿܼ±Á¶»ç¿¡ ÀÇÇØ »ý±â´Â ±¤¼±°¢È­Áõ¿¡¼­ ¹ß»ý°¡´ÉÇÏ´Ù. º´¸®Á¶Á÷ÇÐÀû Æ¯¼ºÀ¸·Î¼­ °¢ÁúÀ» »ý¼ºÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • disorganized type schizophrenia
    ºØ±«ÇüÁ¤½ÅºÐ¿­º´
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • extroverted type
    ¿ÜÇâÇü
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷, °ñÁö1Çü½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷, °ñÁö2Çü½Å°æ¼¼Æ÷
  • hyperlipidemia type I
    1Çü°íÁöÇ÷Áõ
  • hyperlipidemia type IV
    4Çü°íÁöÇ÷Áõ
  • hyperlipidemia type V
    5Çü°íÁöÇ÷Áõ
  • hypertrophic type
    ºñ´ëÇü
  • hebephrenic type schizophrenia
    ÆÄ°úÇüÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • introversion type
    ³»ÇâÇü
  • intuitive type
    Á÷°üÇü
  • linear type constitution
    ¼±ÇüüÇü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • killer cell
    »ìÇØ¼¼Æ÷
  • Kupffer's cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
  • neuroendocrine cell
    ½Å°æ³»ºÐºñ¼¼Æ÷
  • packed red blood cell
    ³óÃàÀûÇ÷±¸
  • parietal cell
    º®¼¼Æ÷
  • perivascular cell
    Ç÷°üÁÖÀ§¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • polynucleated cell
    ¹µÇÙ¼¼Æ÷
  • prickle cell
    °¡½Ã¼¼Æ÷
  • principal cell
    ÁÖ¼¼Æ÷, À¸¶ä¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • disorganized type schizophrenia
    ºØ±«Á¤½ÅºÐ¿­º´
  • dromedary type
    ´ÜºÀÇü
  • dysplastic type
    Çü¼ºÀÌ»óÇü
  • expansive type
    °ú´ëÇü
  • extroverted type
    ¿ÜÇâÇü
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • hebephrenic type schizophrenia
    ÆÄ°úÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • holomyarian type
    ¿ÏÀü±ÙÀ°Çü
  • hypertrophic type
    ºñ´ëÇü
  • tuberculin-type hypersensitivity
    (¢¡delayed-type hypersensitivity) Áö¿¬°ú¹Î
  • introversion type
    ³»ÇâÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Mobitz type II SA block
    ¸ðºñÃ÷ ¥±Çü µ¿¹æÂ÷´Ü.
  • Ogawa type
    ¿À°¡¿ÍÇü
  • RF coil type
    °íÁÖÆÄ ÄÚÀÏ À¯Çü
  • T-type channel
    T-Çü Åë·Î
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
  • golgi type i neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • golgi type ii neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
  • hebephrenic type
    ÆÄ°úÇü(÷òÍþúþ)
  • hemochorial type
    À¶Ç÷¸ðÇü(ëÖúìÙ¾úþ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • chronic administration
    ¸¸¼ºÅõ¿©.
  • chronic ambulatory peritoneal dialysis
    Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼®
  • chronic arterial occlusion
    ¸¸¼ºµ¿¸ÆÆó¼â.
  • chronic atrophic gastritis
    ¸¸¼ºÀ§Ã༺ À§¿°(¡­ê×õêàõêÖæú).
  • chronic atrophic laryngitis
    ¸¸¼ºÀ§Ãà(¼º)Èĵο°
  • chronic bactrial prostatitis
    ¸¸¼º ¼¼±Õ¼º Àü¸³¼±¿°
  • chronic bronchitis
    ¸¸¼º±â°üÁö¿°(¡­Ñ¨Î·ò¨æú).
  • chronic bullous dermatis of childhood
  • chronic bullous dermatosis of childhood
    ¸¸¼º ¼Ò¾Æ ¼öÆ÷¼º ÇǺκ´
  • chronic carrier
    ¸¸¼ºº¸±ÕÀÚ(ÊÙËÓË»Ëö).
  • chronic carrier
    ¸¸¼ºº¸±ÕÀÚ(¡­ÜÁжí­).
  • chronic closed angle glaucoma
    ¸¸¼ºÆó¼â°¢³ì³»Àå
  • chronic conjunctivitis
    ¸¸¼º°á¸·¿°
  • chronic constrictive pericarditis
    ¸¸¼º±äÃ༺ ½É¸·¿°(Ø·àõÑÌõêàõãýدæú).
  • chronic cystic mastitis
    ¸¸¼º³¶¼º À¯¹æ¿°(¡­³¶¼ºÀ¯¹æ¿°).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Interstitial cell [Dark cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Interstitial cell [Leydig`s cell]
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Bronchiolar cell [Clara cell]
    ¼¼±â°üÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐºñ¼¼Æ÷
  • Parafollicular cell [Calcitonin cell]
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Neurolemmal cell [Schwann`s cell]
    ½Å°æÁý¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æÃʼ¼Æ÷
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Dark cell [Norepinephrine cell]
    ¾îµÎ¿î¼¼Æ÷ [³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷(³ë¸£¿¡Çdz×ÇÁ¸°ºÐºñ¼¼Æ÷)
  • Supporting cell [Sertoli cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Striated muscle cell
    °¡·Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ⱦ¹®±Ù¼¼Æ÷
  • Sensory epithelial cell
    °¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢»óÇǼ¼Æ÷
  • Cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁú³»ºÐºñ¼¼Æ÷
  • Nodal cell
    °áÀý¼¼Æ÷
    [¿¾ ¿ë¾î] °áÀý¼¼Æ÷
  • Granule cell
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³¼¼Æ÷
  • Granular lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • amplifier T cell
    Áõ½Ä T ¼¼Æ÷(ñòãÖ T á¬øà)
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • APUD cell
    APUD ¼¼Æ÷(á¬øà)
  • argentaffin cell
    ¾Æ¸£Á¨Å¸ÇÉ ¼¼Æ÷(á¬øà)
  • autosynthetic cell
    ÀÚ°¡ÇÕ¼º¼¼Æ÷ (í»Ê«ùêà÷á¬øà)
  • barrier layer cell
    À庮Ãþ(î¡Ûúöµ) ¼¼Æ÷(á¬øà)
  • B cell
    B ¼¼Æ÷(á¬øà)
  • cell adhesion
    ¼¼Æ÷ºÎÂø(á¬øàÜõó·)
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • goblet cell
    ¼úÀܼ¼Æ÷, ¹è³¶¼¼Æ÷
  • granular cell myoblastoma
    °ú¸³¼¼Æ÷±Ù¸ð¼¼Æ÷Á¾
  • granulosa cell
    °ú¸³¸·¼¼Æ÷
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • islet cell
    µµ¼¼Æ÷
  • islet cell adenoma
    Ãéµµ¼¼Æ÷¼±Á¾
  • islet cell carcinoma
    µµ¼¼Æ÷¾ÏÁ¾
  • Langerhans' cell
    ¶û°Ô¸£Çѽº¼¼Æ÷
  • Langhans' glant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • large cell
    ´ë¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ¾ç¼¼Æ÷, ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ±¸¾ç¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    À¯µ¹ºÀ¼Ò
  • mastoid cell
    À¯(¾ç)µ¹(±â)ºÀ¼Ò
  • nerve cell
    ½Å°æ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CML carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat...
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
CPH Certificate in Public Health; chronic paroxysmal hemicrania; chronic persistent hepatitis; chronic p...
CCH C-cell hyperplasia; chronic chloride hemagglutination; chronic cholestatic hepatitis
CCS Canadian Cardiovascular Society; casualty clearing station; cell cycle specific; cholecystosonograph...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CMML Chronic myelomonocytic leukaemia
CNL Chronic neutrophilic leukaemia
JCML Juvenile chronic myelogenous leukaemia
JCML Juvenile chronic myeloid leukaemia
ATL Adult T Cell Leukaemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • iris-type
    ȫä ¸ð¾ç
  • Jaeger's test type
    ¿¹°Å ¹®ÀÚ
    ½Ã·Â °Ë»ç¿¡ »ç¿ëµÇ´Â ´ë¼ÒÀÇ ¹®ÀÚ¸¦ ´Ã¾î³õÀº Ç¥.
  • jealous type
    ÁúÅõÇü
  • knife edge type
    ³ªÀÌÇÁ ¿¡Âî ŸÀÔ
    finishing lineÀÇ ÀÏÁ¾ÀÌ´Ù.
  • lepromatous type
    ³ªÁ¾Çü
  • localized type
    ±¹¼ÒÇü
  • major type
    ÁÖµÈ ÇüÅÂ
  • membrane type
    ¸·Çü
  • mesial step type
    ±Ù½É °è´ÜÇü
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü
  • morphea-like type
    ¹Ý»ó °æÇÇÁõ °°Àº ÇüÅÂ
  • multifocal type
    ´Ù¹ß¼º
  • muscle tension type headache
    ±Ù ±äÀ强 µÎÅë
    ÈĵκÎ, Ç׺ÎÀÇ Áö¼ÓÀûÀÎ ¾Ð¹Ú°¨, ±³¾×°¨À» È£¼ÒÇÑ´Ù. ÀÌ ÁõÀÇ È¯ÀÚ´Â ½Å°æÁú·Î ±äÀåÇϱ⠽¬¿î »ç¶÷¿¡°Ô ¸¹°í °³Ã¼ÀÇ ±Ù±äÀ强¼ÒÀΰú ¾î¿ï¾îÁ® ±ÙÀÇ Áö¼ÓÀû ¼öÃà°ú ±ÙÀÇ ¼øÈ¯ ºÎÀü ¡æ ÅëÁõ ¹°Áú ¹ß»ý ¡æ ÅëÁõ ¡æ ±Ù ¼öÃàÀ̶ó´Â ¾Ç¼øÈ¯ÀÌ Çü¼ºµÇ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù. Á÷¾÷¿¡ µû¸¥ ºÎÀÚ¿¬½º·¯¿î ÀÚ¼¼°¡ °ü·ÃÀÌ ÀÖ´Â °æ¿ìµµ ¸¹°í ½Åü, ½É¸®Àû ¾çÃø¸éÀ¸·ÎºÎÅÍÀÇ Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹´Ù.
  • muscular type of vein
    ±ÙÀ°Çü Á¤¸Æ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
acute promyelocytic leukaemia Leukaemia presenting as a severe bleeding disorder, with infiltration of the bone marrow by abnormal promyelocytes and myelocytes, a low plasma fibrinogen, and defective coagulation.
(05 Mar 2000)
aleukaemic leukaemia Leukaemia in which abnormal (or leukaemic) cells are absent in the peripheral blood.
(05 Mar 2000)
avian leukaemia-sarcoma complex A term applied to a group of transmissible virus-induced diseases of chickens causing sarcoma, myeloblastosis, erythroblastosis, leukosis, osteopetrosis, and lymphomatosis. These agents are closely related viruses (avian leukosis-sarcoma virus) causing prolferation of immature erythroid, myeloid, or lymphoid cells, a division of the RNA tumour viruses (subfamily Oncovirinae) causing the avian leukosis-sarcoma complex of diseases; the viruses are subgrouped according to antigenic characteristics and growth in defined types of tissue culture cells.
Synonym: avian erythroblastosis virus, avian leukosis-sarcoma virus, avian lymphomatosis virus, avian myeloblastosis virus, avian sarcoma virus, fowl erythroblastosis virus, fowl lymphomatosis virus, fowl myeloblastosis virus.
(05 Mar 2000)
avian leukaemia virus <virology> Group of C type RNA tumour viruses (Oncovirinae) that cause various leukaemias and other tumours in birds.
The acute leukaemia viruses, that are replication defective and require helper viruses, include avian erythroblastosis (AEV), myeloblastosis (AMV) and myelo cytomatosis viruses.
AEV carries two transforming genes, v erbA and v erbB, the cellular homologue of the latter is the structural gene for the epidermal growth factor receptor. AMV carries v myb and causes a myeloid leukaemia, avian myelocytomatosis virus carries v myc.
The avian lymphatic leukaemia viruses (ALV) are also Retroviridae but are replication competent and induce neoplasia only after several months, they often occur in conjunction with replication defective leukaemia viruses.
(02 Jan 1998)
basophilic leukaemia A form of granulocytic leukaemia in which there are unusually great numbers of basophilic granulocytes in the tissues and circulating blood; in some instances, the immature and mature basophilic forms may represent from 40 to 80% of the total numbers of white blood cells.
Synonym: mast cell leukaemia.
(05 Mar 2000)
bovine leukaemia A lymphoid neoplastic disease in cattle caused by the bovine leukaemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukaemia but the presence of malignant cells in the blood is not a consistent finding.
(12 Dec 1998)
bovine leukaemia virus A type C retrovirus in the subfamily Retrovirinae, commonly infecting cattle, especially dairy cows; in a small proportion of infected cattle, it will cause enzootic bovine leukosis.
Synonym: bovine leukosis virus.
(05 Mar 2000)
cancer, leukaemia Leukaemia is a cancer of the white blood cells. Leukaemias are grouped by how quickly the disease develops (acute or chronic) as well as by the type of blood cell that is affected. People with leukaemia are at significantly increased risk for developing infections, anaemia, and bleeding. Diagnosis of leukaemia is supported by findings of the medical history and examination, and examining blood under a microscope. Leukaemia cells can be detected and further classified with a bone marrow aspiration and/or biopsy. most patients with leukaemia are treated with chemotherapy. Some patients also may have radiation therapy and/or bone marrow transplantation.
(12 Dec 1998)
radiation leukaemia virus A murine leukaemia virus isolated from radiation-induced lymphomas in c57bl mice. It is leukemogenic, thymotrophic, can be transmitted vertically, and replicates only in vivo.
(12 Dec 1998)
Maloney leukaemia virus A retrovirus associated with leukaemia in rodents.
(05 Mar 2000)
Rauscher leukaemia virus An RNA retrovirus associated with leukaemia in rodents; similar to Friend virus.
Synonym: Rauscher's virus.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cell
    ÀÛÀº¹æ;¾ÏÀÚ(¼öµµ¿ø ºÎ¼ÓÀÇ);»ç½Ç;¿ÀµÎ¸·Áý;¹«´ý;(±³µµ¼ÒÀÇ)µ¶¹æ;(¹úÁýÀÇ)±¸¸Û;²É°¡·çÁÖ¸Ó´Ï;ÀüÁö;¼¼Æ÷;(Á¶Á÷³»ÀÇ)ÀÛÀº °øµ¿;¼¼Æ÷(°ø»ê´ç µîÀÇ);°¡½ºÅë(±â±¸ÀÇ);ºñÆ®ÀÇ ±â¾ï¼ÒÀÚ;µ¶¹æ»ìÀÌÇÏ´Ù;ÀÛÀº ¹æ¿¡ Ʋ¾î¹ÚÈ÷´Ù
  • cell body
    ¼¼Æ÷ÀÇ
  • cell cycle
    ¼¼Æ÷ÁÖ±â;ºÐ¿­ÁÖ±â
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
  • cell sorter
    ¼¼Æ÷ ºÐº°±â
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cell wall
    ¼¼Æ÷º®
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • closed-cell
    µ¶¸³±âÆ÷ÀÇ;¹ÐÆó±âÆ÷ÀÇ(¼ÒÀç´Â ÇÃ¶ó½ºÆ½µî)
  • complementary cell
    º¸Á· ¼¼Æ÷
  • condemned cell (ward)
    »çÇü¼ö °¨¹æ
  • corticopontine cell
    ÇÇÁú±³¼¼Æ÷(´ë³ú ÇÇÁú¿¡ ÀÖÀ¸¸ç ½Ã°¢ ÀÚ±ØÀ» ³ú±³¿¡ º¸³¿)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á